SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is experiencing a volatile sell-off as investors weigh strong cyclical demand against market-wide risk aversion and speculative fears that AI efficiency algorithms could eventually dampen long-term memory requirements. The community remains deeply divided, with many bullish investors viewing the sharp retracement as a structural buying opportunity due to strong fundamentals, while others fear a technical breakdown and further downward pressure driven by broader geopolitical instability.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending as investors weigh significant supply chain constraints, specifically a deepening CPU shortage and concurrent price hikes, against the stock's persistent price volatility tied to macroeconomic and geopolitical factors. Community discussion remains polarized, with many traders focusing on the company's long-term foundry turnaround potential and advanced packaging technology as catalysts, while others remain cautious due to short-term downward pressure and broader market instability.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is generating significant community buzz due to its ambitious expansion into Finland, where it is constructing one of Europes largest AI compute hubs to support advanced AI infrastructure. While the stock has experienced recent volatility amid broader market corrections and sector-wide profit-taking, bullish investors remain focused on the companys strategic partnerships and multi-year growth runway as a key player in the AI cloud market.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is currently under intense scrutiny as market participants react to geopolitical instability and shifting narratives surrounding the U.S. military operation in Iran. Investors and community members are actively debating the economic implications of the Strait of Hormuz conflict, while social media channels are flooded with polarizing discourse regarding the administration's foreign policy, potential war-time spending, and broader political controversies.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS Health is attracting significant attention as investors react to a mix of positive earnings guidance and strategic shifts, including a major acquisition of Rite Aid assets and a new partnership on a fertility program. While some market participants are closely monitoring the impact of potential policy changes on the healthcare sector, the broader community remains focused on CVS's ability to maintain momentum and improve margins through its vertically integrated operations.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is under significant pressure as investors rotate out of high-beta semiconductor equipment stocks amid mounting industrial headwinds and broader risk-off sentiment. The community is actively debating the company's valuation, questioning whether current price levels offer a buying opportunity or if the sector's structural reliance on capital expenditures is facing a period of cooling momentum.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is capturing market attention as investors react to a strategic leadership shift, including a C-suite overhaul and workforce restructuring aimed at refocusing on store-level operations and growth. The stock remains a focal point for the community, with active debate centering on the company's turnaround potential under new leadership, the impact of its evolving retail media strategy, and conflicting perspectives on whether ongoing consumer headwinds and brand reputation challenges present a buying opportunity or a deeper value trap.

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Ginkgo Bioworks is seeing intense market debate as investors weigh the company's aggressive pivot toward autonomous AI-driven labs and biosecurity against ongoing concerns regarding high cash burn and previous dilution. While some community members view recent technological benchmarks and strategic government-linked initiatives as proof of a long-term platform inflection, others remain deeply skeptical, viewing the stock as a speculative instrument and maintaining a bearish outlook driven by its past financial performance.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is currently a central focus for market participants due to its aggressive Ethereum accumulation strategy and the recent launch of its institutional staking platform, MAVAN. While the company is actively deploying capital to expand its crypto infrastructure, the community remains sharply divided, with bulls highlighting the long-term institutional conviction while bears express intense frustration over share dilution and the stock's persistent price underperformance relative to ETH.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is trending as the community highlights the platform's role in the real-world asset (RWA) sector and its partnerships with institutional giants like BlackRock and Franklin Templeton. While many investors are optimistic about long-term growth and potential tokenized asset adoption, ongoing discussions reflect frustration over current price volatility and upcoming token unlocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it...

<ul class="summary-bullets"><li>Michael Hearne has been appointed Chief Financial Officer, replacing Joe Miller.</li><li>Decision to remove Greenleaf and install Tang as CEO represents a “complete validation” of concerns raised for nearly three years, major shareholder MKT Capital said in a statement.</li><li>The company is looking to initiate a clinical study of Aritinercept for an autoimmune disease in the first half of 2026.&nbsp;</li></ul>Aurinia Pharmaceuticals (AUPH) drew strong retail interest on Monday after naming Kevin Tang as Chief Executive Officer, fueling investor hopes of a “new positive era” for the company.<a href="https://stocktwits.com/symbol/AUPH">AUPH stock</a> was up more than 6% at the time of writing.Tang, who is also the Chair of the Board, will replace Peter Greenleaf, who has been the company’s CEO for the past 7 years. Tang, an industry veteran, previously served as Chairman of La Jolla Pharmaceutical Company from 2014 through its acquisition by Innoviva in 2022.In 2013, Tang founded Odonate Therapeutics and served as its Chairman and CEO through 2022. Mr. Tang also co-founded Ardea Biosciences in 2006 and Heron Therapeutics in 2009. From 2009 through its acquisition by Keenova Therapeutics in 2010, Tang served as Director of Penwest Pharmaceuticals Co.Among other changes, Michael Hearne has been appointed Chief Financial Officer, replacing Joe Miller. Meanwhile, Ryan Cole was appointed as Chief Operating Officer, and Thomas Wei took over as Chief Scientific Officer.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment flipped to ‘bullish’ from ‘bearish,’ amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/AUPH_jpg_4ef07ce8ea.webp" alt="AUPH.jpg">One user speculated on the implications of the management change for the company, akin to the potential for it to go private.<stembedurl>https://stocktwits.com/US_Bull/message/648264487</stembedurl>Another user said, “Hopefully this starts the beginning of a new positive era”.<stembedurl>https://stocktwits.com/cjohoya/message/648275231</stembedurl>In 2021, Aurinia Pharmaceuticals launched LUPKYNIS, an FDA-approved oral treatment for adults with active Lupus Nephritis. The company also plans to begin a clinical study of Aritinercept for an autoimmune disease in the first half of 2026. Aurinia reported its first full-year profit in December 2024.<h2 class="st-heading-2">MKT’s Statement On Management Changes</h2>MKT Capital, a major long-term shareholder of Aurinia, issued a statement following the appointment of Kevin Tang as CEO.“Today marks a watershed moment for Aurinia shareholders. Since 2019, we have tirelessly advocated for accountability, disciplined capital allocation, and genuine alignment between management and the true owners of this Company – its shareholders. The Board’s decision to remove CEO Peter Greenleaf and his executive team, and to install Chair Kevin Tang as CEO, represents a complete validation of the concerns we have raised for nearly three years,” said Antoine Khalife, Founder of MKT Capital.In April 2025, MKT Capital announced its intention to withhold support for Greenleaf at the 2025 Annual General Meeting.Year-to-date, the stock has fallen 6.5%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nvda-stock-200-dma-rebound-ai-factories-deal/cZ3mgN2RI0Z">NVDA Stock Rebounds But Remains Below Key Support For Second Session: Retail Sees Massive Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aurinia Pharmaceuticals logo is seen displayed on a smartphone screen

AUPH Stock Rallies After CEO Shake-Up: Retail Bulls Bet On Turnaround

Aurinia Pharmaceuticals named Kevin Tang as its Chief Executive Officer, replacing Peter Greenleaf.

Equity

Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning

Aurinia Pharmaceuticals shares are trading higher Monday after announcing a leadership transition seen as a sign of continuity and strategy.read more...

Aurinia Announces Management Transition

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced today that Kevin Tang, Aurinias Chair of the Board, will succeed Peter Greenleaf as Chief Executive Officer. Peter will continue as a consultant...

Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Passes Below 200-Day Moving Average - Here's What Happened

Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Crosses Below 200-Day Moving Average - Time to Sell...

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Average Recommendation of "Hold" from Analysts

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) (TSE:AUP) have been assigned a consensus rating of "Hold" from the six analysts that are currently covering the company...

Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Passes Below 50-Day Moving Average - Should You Sell?

Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Crosses Below 50 Day Moving Average - Here's What Happened...

Aurinia Pharmaceuticals (NASDAQ:AUPH) Director Buys $7,224,981.61 in Stock

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) (TSE:AUP) Director Kevin Tang purchased 516,439 shares of Aurinia Pharmaceuticals stock in a transaction dated Friday, February 27th. The...

GSA Capital Partners LLP Trims Stake in Aurinia Pharmaceuticals Inc $AUPH

GSA Capital Partners LLP trimmed its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) (TSE:AUP) by 95.9% in the 3rd quarter, according to its most recent 13F filing with the...

Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Earnings Results

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) (TSE:AUP) issued its quarterly earnings results on Thursday. The biotechnology company reported $1.53 earnings per share (EPS) for the quarter...

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Patrick OShaughnessy - @patrick_oshag on X

Citrini - @Citrini7 on X

Bucco Capital - @buccocapital on X

Joe Weisenthal - @TheStalwart on X

The must-watch individual or show that brings entertainment to finance. This award celebrates the content you look forward to daily - bringing a sharp market edge to engaging discussions. 

Current Price	$13.98
Prev Close	$14.27
Open	$14.30
Dividend Yield	0.00%
50-Day Moving Average	$14.48
Beta	0.84
Avg. Volume	899,237.89
PE Ratio	6.73

52-Week High	$16.54
52-Week Low	$6.83
Market Capitalization	$1.9B
EPS (Annual)	$2.07
Price to Book	3.18
Revenue Per Employee	$2.21M

AUPH
Aurinia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AUPH News

AUPHAurinia Pharmaceuticals Inc